| 764 | 4 | 207 |
| 下载次数 | 被引频次 | 阅读次数 |
评价BD‐77雾化吸入给药对呼吸道合胞病毒(Respiratory syncytial virus,RSV)及脂多糖(Lipopolysaccharide,LPS)致小鼠肺炎的治疗作用，为BD‐77的进一步开发提供实验依据。建立RSV及LPS滴鼻感染致小鼠肺炎模型，采用肺指数、肺指数抑制率、病毒载量、肺组织炎症因子等指标评价BD‐77的药理作用。BD‐77雾化吸入给药75 mg·mL‐1、37.5 mg·mL‐1两个剂量组可显著降低RSV感染小鼠肺指数、病毒载量和炎症因子释放。BD‐77静脉注射150 mg/(kg·d)、75 mg/(kg·d)两个剂量组对LPS引起的小鼠肺炎具有保护作用。BD‐77对RSV及LPS致小鼠肺炎均具有显著的保护作用。
Abstract：To study the protective effect of BD‐77 on pneumonia induced by respiratory syncytial virus (RSV) and lipopolysaccharide (LPS) in mice,and to provide experimental basis for further development of BD‐77.A mouse model of pneumonia induced by RSV and LPS was established by nasal drops.The pharmacological effects of BD‐77 were evaluated by lung index,lung index inhibition rate,viral load and inflammatory factors of lung tissue.Aerosol administration of BD‐77 at 75 mg·mL‐1 and 37.5 mg·mL‐1 for 25min could significantly reduce lung index,viral load and inflammatory factor release of RSV‐infected mice.Intravenous injection of 150mg/(kg·d)and 75 mg/(kg·d) of BD‐77 had protective effects on lipopolysaccharide (LPS) induced pneumonia in mice.BD‐77 has significant protective effect on RSV and LPS induced pneumonia in mice.
[1] Young M, Smitherman L. Socioeconomic impact of rsv hospitalization[J]. Infect Dis Ther, 2021,10(Suppl 1):35-45. DOI:10.1007/s40121-020-00390-7.
[2] Van Woensel J, Kimpen J. Therapy for respiratory tract infections caused by respiratory syncytial virus[J]. Eur J Pediatr, 2000,159(6):391-398. DOI:10.1007/s004310051295.
[3] Fitzpatrick T, McNally JD, Stukel TA, et al. Family and child risk factors for early-life rsv illness[J].Pediatrics. 2021,147(4):e2020029090. DOI:10.1542/peds.2020-029090.
[4]李有，Xin Wang,Dianna M.Blau等.2019年全球、地区和国家5岁以下儿童呼吸道合胞病毒引发急性下呼吸道感染疾病负担研究的系统分析[J].中国病毒病杂志，2023,13(02):81-95. DOI:10.16505/j. 2095-0136.2023.2001.
[5] Zhang S, Akmar LZ, Bailey F, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level:a systematic review and meta-analysis[J]. J Infect Dis, 2020,222(Suppl 7):S680-S687. DOI:10.1093/infdis/jiz683.
[6] Rudd PA, Chen W, Mahalingam S. Mouse and cotton rat models of human respiratory syncytial virus[J].Methods Mol Biol, 2016,33(1442):209-217. DOI:10.1007/978-1-4939-3687-8_15.
[7] Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it[J]. Nat Rev Microbiol,2019,17(4):233-245. DOI:10.1038/s41579-019-0149-x.
[8] Jorquera PA, Tripp RA. Respiratory syncytial virus:prospects for new and emerging therapeutics[J]. Expert Rev Respir Med, 2017,11(8):609-615. DOI:10.1080/17476348.2017.1338567.
[9]杨筱萌，罗语思，郭名扬，等.人呼吸道合胞病毒感染致小鼠急性肺损伤动物模型的建立[J].中国病原生物学杂志，2022, 17(09):993-998+1004. DOI:10.13350/j.cjpb.220901.
[10]高微微，邹映雪.儿童呼吸道合胞病毒感染的药物治疗研究进展及其预防策略[J].现代药物与临床，2023,38(08):2073-2079. DOI:10.7501/j. issn. 1674-5515.2023.08.043.
[11]Baraldi E, Checcucci Lisi G, Costantino C, et al. RSV disease in infants and young children:can we see a brighter future?[J]. Hum Vaccin Immunother. 2022,18(4):2079322.DOI:10.1080/21645515.2022.2079322.
[12]Law BJ, Wang EE, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus(rsv)infection? an analysis using the pediatric investigators collaborative network on infections in canada(picnic)rsv database[J]. Pediatrics,1997,99(3):E7. DOI:10.1542/peds.99.3.e7.
[13]Moler FW, Steinhart CM, Ohmit SE, et al.Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure.pediatric critical study group.[J]. J Pediatr. 1996,128(3):422-428. DOI:10.1016/s0022-3476(96)70294-9.
[14]张婉莹，田曼.呼吸道合胞病毒感染的防治药物研究进展[J].中国病毒病杂志，2023,13(02):101-107.DOI:10.16505/j.2095-0136.2023.0014.
[15]Garegnani L, Styrmisdóttir L, Roson Rodriguez P, et al. Palivizumab for preventing severe respiratory syncytial virus(rsv)infection in children[J]. Cochrane Database Syst Rev,2021,11(11):CD013757. DOI:10.1002/14651858.
[16]Zhang G, Li Y, Chen T, et al. Comparative study of the efficacy and pharmacokinetics of reduning injection and atomization inhalation.[J]. Biomed Pharmacother,2019,38(118):109226. DOI:10.1016/j. biopha. 2019.109226.
[17]孙静，赵荣华，时宇静，等.热毒宁吸入溶液对甲型流感病毒A/PR/8/H1N1感染所致小鼠病毒性肺炎的药理作用研究.[J].中国药物警戒，2021,18(12):1101-1105. DOI:10.19803/j.1672-8629.2021.12.01.
[18]莫荣浩，陈洁琳，徐琳，等.呼吸道合胞病毒载量与儿童下呼吸道感染严重程度的临床分析[J].中国实用儿科杂志，2023,38(11):853-857. DOI:10.19538/j.ek2023110610.
[19]刘培.呼吸道合胞病毒肺炎新生儿IL-6、CRP水平与肺功能关系[J].辽宁医学杂志，2022,36(04):93-95.
[20]林洁，董琳，李海燕，等.重症呼吸道合胞病毒肺炎临床特点及抗菌药物使用分析[J].临床儿科杂志，2011,29(05),454-458.
[21]路雅菲，薛江东，毕玉海.季节性流感病毒与其他病原混合或继发感染的研究进展与思考[J].微生物学报，2022,62(12):4731-4739. DOI:10.13343/j. cnki.wsxb.20220210.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004443
中图分类号:R563.1
引用信息:
[1]孙静,赵荣华,孙建辉,等.雾化吸入给药BD-77对呼吸道合胞病毒感染及LPS致小鼠肺炎的治疗作用[J].病毒学报,2024,40(01):45-50.DOI:10.13242/j.cnki.bingduxuebao.004443.
基金信息:
国家自然科学基金项目（项目号：82104500）,题目：PINK-1/Parkin调节NLRP3炎症小体过度激活在冠状病毒性肺炎中的作用及马鞭草苷的干预研究~~
2024-01-05
2024-01-05
2024-01-05